Relmada names Jørn Skibsted Jakobsen chief development officer ahead of NDV-01 Phase 3
Relmada Therapeutics announced on November 16, 2026 that the former global clinical development leader of ADSTILADRIN will oversee the company's pipeline as it prepares a Phase 3 program for NDV-01 in bladder cancer.
SEC filing